Mel-18 has been implicated in several processes in tumor progression, in which the Akt pathway is involved as an important key molecular event. However, the function of Mel-18 in human cancers has not been fully established yet. Here, we examined the effect of Mel-18 on tumor angiogenesis in human breast cancer, and found that Mel-18 was a novel regulator of HIF-1a. Mel-18 negatively regulated the HIF-1a expression and its target gene VEGF transcription during both normoxia and hypoxia. We demonstrated that Mel-18 regulated the HIF-1a expression and activity via the PI3K/Akt pathway. Loss of Mel-18 downregulated Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) expression, consequently activating the PI3K/Akt/MDM2 pathway, and leading to an increase of HIF-1a protein level. Mel-18 modulated the HIF-1a transcriptional activity via regulating the cytoplasmic retention of FOXO3a, a downstream effector of Akt, and recruitment of HIF-1a/CBP complex to the VEGF promoter. Furthermore, our data shows that Mel-18 blocked tumor angiogenesis both in vitro and in vivo. Mel-18 overexpression inhibited in vitro tube formation in human umbilical endothelial cells (HUVECs). Xenografts in NOD/SCID mice derived from stably Mel-18 knocked down MCF7 human breast cancer cells showed increased tumor volume, microvessel density, and phospho-Akt and HIF-1a expression levels. In conclusion, our findings provide that Mel-18 is a novel regulator of tumor angiogenesis through regulating HIF-1a and its target VEGF expressions mediated by the PTEN/PI3K/Akt pathway, suggesting a new tumor-suppressive role of Mel-18 in human breast cancer.
Introduction
Mel-18 is a member of the polycomb group proteins belonging to the polycomb repressive complex-1 (ValkLingbeek et al., 2004) . Polycomb group are chromatinmodifying proteins that form multimeric complexes and repress target genes expression via multiple epigenetic mechanisms, such as histone modifications and DNA methylation. Much evidence has shown that these proteins have a crucial role in tumor development through regulating various cellular processes, such as cell proliferation, invasion and metastasis (Guo et al., 2007a) . Although Mel-18 is 57% homologous to another polycomb repressive complex-1 group protein, Bmi-1, which has been implicated as a putative oncogene (Jacobs et al., 1999) ; it has been suggested that Mel-18 functions as a negative regulator of Bmi-1 via inhibiting c-Myc expression (Guo et al., 2007b) . The role of Mel-18 in human cancer has not yet been fully revealed, but several studies have shown the tumor suppressive activity of Mel-18, unlike Bmi-1. Recently, it has been reported that loss of Mel-18 is closely related to poor prognosis in several human cancers, including prostate, breast and gastric cancers . Furthermore, our previous study indicated that inhibits Akt activity and regulates its downstream molecules, such as GSK-3b and p27 Kip1 in human breast cancer (Hoffmann et al., 2008) . Although we have found that the Akt pathway is essential for the regulation of cancer growth mediated by it has not yet been fully evaluated whether Mel-18 is involved in other oncogenic processes such as tumor angiogenesis even though a recent study showed that Mel-18 enhances angiogenic activity (Jung et al., 2010) .
Tumor angiogenesis is an important process in tumor progression, providing the tumor with oxygen and nutrients by producing and releasing vascular endothelial growth factor (VEGF) that is the stimulator of blood vessel formation (Brahimi-Horn and Pouyssegur, 2009) . It is an essential event for the invasion and metastasis of primary tumors because malignant tumors contain the hypoxia region (Maxwell et al., 2001a) . During hypoxia, the VEGF expression is induced by hypoxia-inducible factor 1 (HIF-1), which is one of the main regulators of oxygen homeostasis (Brahimi-Horn and Pouyssegur, 2009) . HIF-1 consists of an oxygensensitive a subunit, which determines the activity of HIF-1, and a b subunit, which is constitutively expressed. During hypoxia, HIF-1a is stabilized and forms a dimer with HIF-1b and then binds to the hypoxia response element (HRE) in HIF-1 target genes with other transcription factors, such as p300/CBP (Arany et al., 1996) . The stability and activity of HIF-1a are regulated by post-translational modifications, such as hydroxylation, acetylation, ubiquitination and phosphorylation (Ravi et al., 2000) . For example, in normoxia, Von Hippel-Lindau (VHL) protein recognizes the hydroxylation of HIF-1a by prolyl hydroxylase enzymes and then induces rapid proteasomal degradation of HIF-1a through ubiquitination (Maxwell et al., 2001b; Pugh and Ratcliffe, 2003) . FIH-1 also regulates HIF-1a hydroxylation and inhibits p300/CBP that increases transcription of HIF-1a target genes, binding to HIF-1a (Lee et al., 2009) . Activation of extracellular response kinase (ERK) increased HIF-1a phophorylation and stability, and enhanced its transcriptional activity by increasing the affinity of HIF-1a with CBP (Richard et al., 1999) . Akt signaling is also very important in HIF-1a regulation through the multiple targets downstream, such as MDM2, mTOR/p70S6K, and FOXO3a (Brunet et al., 1999; Ashcroft et al., 2002; Li et al., 2008) .
In this study, we investigated the role of Mel-18 in tumor angiogenesis and found that loss of Mel-18 controlled the expression and transcriptional activity of HIF-1a, in an Akt-dependent manner, and led to a consequent increase of microvessel density via upregulation of VEGF. Therefore, we propose that Mel-18 is a novel negative regulator of HIF-1a via the inhibition of Akt, and has an important role in tumor angiogenesis.
Results
Loss of Mel-18 enhances the HIF-1a protein expression and VEGF transcription in breast cancer cells As expression of HIF-1a and HIF-1a-dependent transcriptional activity can be regulated by PKB/Akt activity (Zhong et al., 2000) , we hypothesized that Mel-18 may be involved in the regulation of HIF-1a via the Akt pathway. To determine whether Mel-18 regulates HIF-1a and its target VEGF expression, we established Mel-18 knockdown MCF7 cell lines using lentiviral short hairpin RNA (shRNA) and Mel-18 overexpressing SK-BR-3 cell lines by using retroviral vector encoding Mel-18 cDNA, because MCF7 cells and SK-BR-3 cells have high and low endogenous expression of Mel-18, respectively (Lee et al., 2008) . In both normoxia and hypoxia condition with CoCl 2 treatment, the protein level of HIF-1a was increased and its messenger RNA (mRNA) level was unchanged, whereas both protein and mRNA level of VEGF was increased by the loss of Mel-18 in MCF7 cells. Similarly, the expression of HIF-1a and VEGF were reduced by overexpression of Mel-18 in SK-BR-3 cells (Figures 1a  and b) . We next investigated the effect of Mel-18 on HIF-1a-dependent transcriptional activity in both cell lines, as assessed by luciferase assay. As a result, loss of Mel-18 increased both the HRE and VEGF promoter activities ( Figure 1c , top panels), and overexpression of Mel-18 decreased their activities (Figure 1c , bottom panels). Because HIF-1a expression was changed at the post-transcriptional level by (Figures 1a and b) , the effect of Mel-18 on HIF-1a protein stability was checked using treatment with cyclohexamide (CHX), an inhibitor of protein synthesis, and we determined that HIF-1a stability was increased by loss of Mel-18 (Figure 1d, left panel) . In addition, the proteasomal blocker, MG132 led to significantly restored reduction of HIF-1a protein by Mel-18 in 293T cell lines (Figure 1d, right panel) . Collectively, these data suggest that Mel-18 enhanced HIF-1a protein degradation and consequently inhibited HIF-1a-dependent VEGF transcription.
Loss of Mel-18 induces HIF-1a expression through upregulation of MDM2 expression mediated by PTEN/Akt signaling We next investigated the factors that might regulate Mel-18-mediated HIF-1a expression. As PTEN, an upstream regulator or Akt, has been suggested as an inhibitor of HIF-1a via inactivating Akt pathway (Fang et al., 2007; Merritt et al., 2010) , we checked the effect of Mel-18 on PTEN expression in MCF7 cells and found that Mel-18 knockdown reduced the PTEN protein levels, but not its mRNA levels, and consequently increased Akt phosphorylation in MCF7 cells (Figure 2a left panels). When measuring the stability of PTEN using the CHX treatment, PTEN was more rapidly degraded by loss of Mel-18 when compared with the control (Figure 2b ). In addition, the PTEN downregulation by Mel-18 blockade was restored by MG132 treatment (Figure 2c ). We next checked the expressions of Akt downstream regulators that are involved in the regulation of HIF-1a expression. We found that MDM2 expression was increased at the protein level in Mel-18 knockdown MCF7 cells (Figure 2a) , and the increased HIF-1a expression by Mel-18 knockdown was abolished by MDM2 downexpression using PI3K inhibitor LY294002 (Figure 2d ). Other Akt downstream regulators of HIF-1a, mTOR and p70S6K, were unchanged by Mel-18 knockdown (data not shown). To confirm that the PTEN/Akt/MDM2 pathway is crucial for the regulation of HIF-1a and its target VEGF by Mel-18, we also established the Mel-18 knockdown ZR-75-1 cells, which are known as PTEN null cells (Li et al., 2007) . In these cells, Mel-18 could not affect Akt phosphorylation and MDM2 expression (Figure 2a , right panels), and also could not alter HIF-1a and VEGF expression (data not shown). In ZR-75-1 cells stably reconstituted with PTEN, however, Mel-18 knockdown was able to activate the PTEN/Akt/ MDM2 pathway (Figure 2a , right panels), and consequently upregulate HIF-1a and VEGF expression (data not shown). Together, these results suggest that loss of Mel-18 enhances HIF-1a expression via the PTEN/Akt/ MDM2 pathway.
Loss of Mel-18 enhances HIF-1a transcriptional activity by increasing FOXO3a phosphorylation via the PTEN/ PI3K/Akt cascade and recruiting CBP at the VEGF promoter region We next investigated the effect of Mel-18 on the expression and activity of HIF-1a-dependent transcriptional regulators. Because the active Akt/FOXO3a pathway has been implicated in the enhancement of the transcriptional activity of the HIF-1a protein (Emerling et al., 2008) , we examined whether the Akt/ FOXO3a pathway was regulated by Mel-18. We found that FOXO3a phosphorylation was negatively regulated by . When treated with LY294002, increased HIF-1a and VEGF protein levels by Mel-18 knockdown were abrogated in MCF7 cells, indicating Akt/FOXO3a signaling-dependent HIF-1a and VEGF regulation by Mel-18 (Figures 2d and 3b) . We also tested to see whether ERK signaling partici- Figure 1a were subjected to immunoblotting (left) and RT-PCR (right) . (b) and (c) To investigate PTEN stability, cells prepared as above were treated with 100 mM CHX for the indicated time and 40 mM MG132 for 3 h before harvest, and the PTEN and Mel-18 protein levels were detected by immunoblotting. (d) The cells were serum-starved for 36 h, and additionally cultured with the same medium containing 40 mM LY294002 or DMSO for 12 h. For stimulation of the Akt pathway, the cells were treated with 10% FBS for 1 h before harvest. The indicated proteins were detected by immunoblotting. All experiments were performed in triplicate. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; shCon, control shRNA; shMel, Mel-18 shRNA. Figure 1 Effect of Mel-18 on HIF-1a expression and its transcriptional activity. (a) MCF7 cells infected with shCon or shMel lentiviruses were serum-starved for 48 h and stimulated with 10% FBS for 1 h. SK-BR-3 cells infected with Con or Mel-18 retroviruses were cultured in 10% serum condition for 48 h. Cell lysates and total RNA from these cells were analyzed for expression of the indicated genes by immunoblotting (top) and RT-PCR (bottom), respectively. (b) Cells under the same conditions as in (a) were treated with 100 mM CoCl 2 for 6 h before harvest, and subjected to immunoblotting (top) and RT-PCR (bottom). (c) Effect of HIF-1a transcriptional activity by Mel-18. Mel-18 knockdown MCF7 cells or Mel-18 overexpressing SK-BR-3 cells were co-transfected with either HRE-luc or VEGF-luc and b-galactosidase constructs for 48 h. In case of Mel-18 knockdown MCF7 cells, they were incubated under a serum starvation condition and then stimulated with 10% FBS for 1 h. For the hypoxic condition, the cells were additionally treated with 100 mM CoCl 2 for 6 h before harvest. Each promoter activity was determined as described in the Materials and methods. *Statistically significant difference of Po0.005 (Student's t-test). (d) HIF-1a degradation following treatment with 10 mM CHX for the indicated time was analyzed by immunoblotting in cells prepared as in (a). To examine the effect of Mel-18 on the proteasomal degradation of HIF-1a, 293T cells transiently co-transfected with HA-Mel-18 and FLAG-HIF-1a under 10% serum conditions for 48 h were treated with 40 mM MG132 for 6 h before harvest. The cell lysates were analyzed by immunoblotting. All experiments were performed in triplicate. con, control; shCon, control shRNA; shMel, Mel-18 shRNA; RLU, relative light units. pated in Mel-18-mediated HIF-1a and VEGF regulation, but ERK activity was unchanged by Mel-18 ( Figure 3a ). Because it has been reported that FOXO3a phosphorylation by Akt impairs its nuclear translocation (Davis et al., 2009) , we next examined the effect of Mel-18 on FOXO3a subcellular localization. The expression of cytoplasmic FOXO3a was increased and nuclear FOXO3a was downregulated by Mel-18 knockdown and this was reversed by LY294002 treatment in MCF7 cells as assessed by immunoblotting ( Figure 3c ). This result was also confirmed by immunocytochemistry ( Figure 3d ). Therefore, we concluded that loss of Mel-18 induces FOXO3a phosphorylation through the activation of Akt and enhances VEGF transcription via the cytoplasmic translocation of FOXO3a. We next explored the effect of Mel-18 on the activity of transcriptional co-activators of HIF-1a, p300/CBP. Under hypoxia condition with CoCl 2 treatment, Mel-18 overexpression suppressed the interaction of CBP with HIF-1a (Figure 3e lane 5 vs 6). Furthermore, Mel-18 overexpression inhibited the recruitment of CBP and HIF-1a to the HRE site of the VEGF-promoter in 293T cells as measured by Chromatin immunoprecipitation (ChIP) assay (Figure 3f , top panels). We also confirmed the opposite effect in loss of Mel-18 in MCF7 cells (Figure 3f , bottom panels). Collectively, these data indicate that Mel-18 suppressed HIF-1a-dependent VEGF transcription via enhancing cytoplasmic retention of FOXO3a, mediated by the PTEN/PI3K/Akt cascade and inhibiting the recruitment of HIF-1a and CBP at the VEGFpromoter. Figure 2d were subjected to immunoblotting with indicated antibodies. (c) The cells were fractionated and the amounts of nuclear and cytoplasmic HIF-1a and FOXO3a were measured by immunoblotting. (d) The cells were subjected to immunocytochemistry. The quantified results of the immunocytochemistry (bottom). (e) 293T cells were transiently co-transfected with FLAG-HIF-1a, HA-Mel-18 and Myc-VHL for 48 h. The cells were either untreated or treated with 100 mM CoCl 2 or 40 mM MG132 for 6 h before harvest. The cell lysates were immunoprecipitated using CBP antibody, and the amount of interaction of the indicated proteins was analyzed by western blot. (f) 293T cells prepared as in (e) (top) and Mel-18 knockdown MCF7 cells under the same conditions as in Figure 1a (bottom) were subjected to ChIP assay with indicated antibodies. ChIP data was quantified by real-time PCR analysis (right). NO Ab, negative control; MG, MG132. All experiments were performed in triplicate. Columns, average of three independent experiments. * ,w Statistically significant difference of Po0.005 compared with shCon and shMel, respectively. con, control;C, Cytoplasm; C þ N, cytoplasm and nucleus; shCon, control shRNA; shMel, Mel-18 shRNA.
Mel-18 interacted with HIF-1a and VHL but did not interfere with the interaction between HIF-1a and VHL Because the VHL protein, which is the known E3 ubiquitin ligase complex, is a key molecular mechanism for the regulation of HIF-1a protein via hydroxylation and ubiquitination (Cockman et al., 2000; Tanimoto et al., 2000) , we examined whether Mel-18 affected the interaction of HIF-1a with VHL. However, in both normoxia and hypoxia condition with CoCl 2 treatment, Mel-18 did not alter the interaction of HIF-1a with VHL (Figures 4a and b) . Furthermore, Mel-18 did not alter HIF-1a ubiqutination by VHL (data not shown). Interestingly, we discovered that Mel-18 interacted with HIF-1a (lanes 4 and 6). Moreover, the interaction between Mel-18 and HIF-1a or VHL was unchanged in both normoxia and hypoxia condition with CoCl 2 treatment. We also confirmed that Mel-18, HIF-1a and VHL constituted a complex in both normoxia and hypoxia condition with CoCl 2 treatment (Figure 4c ). Collectively, these data indicate that Mel-18 interacted with HIF-1a and VHL but did not affect the interaction between HIF-1a and VHL and HIF-1a ubiquitination by VHL.
Mel-18 overexpression inhibits in vitro tube formation and the expression of VEGF in HUVECs Because we found that Mel-18 regulates VEGF via the upregulation of HIF-1a-dependent transcriptional activity, we next investigated the effect of Mel-18 on angiogenesis in HUVECs using in vitro tube formation assay. In contrast to a previous report that Mel-18 enhances tube formation in HUVEC (Jung et al., 2010) , a small quantity of tube formation was observed in Mel-18 overexpressing HUVECs under both normoxia and hypoxia condition with CoCl 2 treatment (Figure 5a ). Furthermore, we confirmed that Mel-18 overexpression reduced the expression of angiogenetic factors, such as HIF-1a and VEGF, through the inactivation of Akt in HUVECs (Figure 5b) . We also performed the in vitro tube formation assay by using HUVECs with conditioned media from Mel-18 knockdown MCF7 cells. We confirmed that the conditioned media from Mel-18 knockdown cells contained a large amount of VEGF more than control cells by using enzyme-linked immunosorbent assay (ELISA) (data not shown), and was sufficient for enhancing tube formation in HUVECs (Figure 5c ). Collectively, these results showed that the expression of Mel-18 affected angiogenesis through the regulation of HIF-1a and VEGF, mediated by the Akt pathway.
Loss of Mel-18 increased tumor volume, microvessel density and the HIF-1a expression level in xenografted tumors To confirm whether the results of the in vitro tube formation assay also matched the in vivo tumor microvessel, we performed xenografts in NOD/SCID mice using Mel-18 knockdown MCF7 breast tumor cells. The mice group injected with Mel-18 knockdown MCF7 cells showed an increase of tumor volume when compared with the control group (Figure 6a) . Furthermore, tumors with loss of Mel-18 showed increased HIF-1a and phospho-Akt expression, and microvascular density (Figure 6b ). Collectively, these results suggest that Mel-18 contributed to the inhibition of tumor angiogenesis through regulating the HIF-1a mediated by the Akt pathway both in vitro and in vivo.
Discussion
In this study, we confirmed that Mel-18 inhibits tumor angiogenesis through the repression of HIF-1a expression and its downstream VEGF transcription both in vitro and in vivo. Our data shows that loss of Mel-18 enhanced Akt phosphorylation and its downstream MDM2 expression via inhibition of the PTEN protein level, and then induced MDM2-mediated HIF-1a expression (Figure 7) . Moreover, Mel-18 controlled the HIF-1a transcriptional activity via the inhibition of FOXO3a phosphorylation mediated by the PTEN/PI3K/Akt pathway and the recruitment of HIF-1a/CBP complex to the VEGF promoter. Therefore, our data show that loss of Mel-18 enhanced tumor angiogenesis by the activation of PTEN/PI3K/Akt signaling.
Here, we suggested that Mel-18 is a novel inhibitor of HIF-1a, a key regulatory factor in tumor angiogenesis. Our data show that the HIF-1a expression is closely regulated by Mel-18 in an Akt/MDM2-dependent manner. In the regulation of HIF-1a protein expression, VHL has been known as the best-described E3 ubiqutin ligase of HIF-1a. However, it was not involved in our system, because Mel-18 interacted with HIF-1a and VHL but did not interfere with interaction between HIF-1a and VHL. It has been demonstrated that the Von Hippel-Lindau protein-independent pathway also plays an important role in controlling the HIF-1a protein level (Yee Koh et al., 2008) . For example, induction of the sensitive to apoptosis gene, a conserved RING finger protein, or GSK-3b promotes HIF-1a ubiquitination and degradation in a VHL-independent manner (Flugel et al., 2007; Tan et al., 2008) . The regulation of HIF-1a expression by MDM2 has been controversial. Previous studies have shown a negative correlation between MDM2 and HIF-1a. Ravi et al. (2000) proposed that MDM2 functions as an E3 ubiquitin ligase of HIF-1a and induced ubiqutinmediated degradation of HIF-1a. Yoo et al. (2004) also suggested that downexpression of MDM2 enhanced HIF-1a expression by Nur77. In contrast, other studies have suggested that the increasing of MDM2 expression by the activation of Akt signaling enhances HIF-1a expression (Ashcroft et al., 2002; Bardos et al., 2004) . MDM2 overexpression restored LY294002-mediated inhibition of VEGF and HIF-1a expression (Skinner , 2004) . According to a recent study, MDM2 is in competition with FIH, which interrupts the interaction between p300 and HIF-1a via hydroxylation of HIF-1a, and increases the expression of HIF-1a (Lee et al., 2009) . Despite its controversial role, it seems clear that MDM2 might be a major enhancer of HIF-1a protein expression in human breast cancer cells, and loss of Mel-18-induced Akt activation might be very important for MDM2-mediated HIF-1a upregulation and induction of tumor angiogenesis.
It is very important that Mel-18 may regulate HIF-1a-dependent transcriptional activity, because the transcription of VEGF, a major angiogenesis regulator, is dominantly regulated by HIF-1a. The p300/CBP, which is known to be a histone acetyltransferase, is a major binding partner of HIF-1a in enhancing HIF-1a-dependent transcriptional activity (Ema et al., 1999) . In addition, it functions as a linker protein between HIF-1a and signal and transducer of transcription 3, another transcriptional regulator of VEGF (Jung et al., 2005) . FOXO3a is another key regulator of HIF-1a transcriptional activity. The phosphorylated FOXO protein by Akt activation is an inactive form that triggers their translocation from the nucleus to the cytoplasm, and then enhances transcriptional activity of FOXO3a target genes (Brunet et al., 1999) . Emrling et al. demonstrated that an increase in HIF-1a transcriptional activity is dependent on the inactivation of FOXO3a, which impedes p300-dependent HIF-1a transcriptional activity in PTEN-null cells (Emerling et al., 2008) . Our data also indicated that the loss of Mel-18-induced cytoplasmic translocation of FOXO3a in an Akt-dependent manner increased p300-dependent HIF-1a transcriptional activity, and finally increased VEGF expression. Taken together, our study supports a novel role for Mel-18 in tumor angiogenesis as an important mechanism in the regulation of HIF-1a expression and transcriptional activity through the activation of Akt/MDM2 and Akt/FOXO3a signal cascades, respectively. It could have crucial implications for the critical role of Mel-18 in tumor development via the regulation of angiogenesis.
According to our previous study, Mel-18 is known to inhibit Akt activity. However, it remains unclear how Mel-18 regulates Akt activity. Here, we have demonstrated that loss of Mel-18 activated the Akt pathway through downregulation of PTEN, demonstrating a novel mechanism of Akt regulation by Mel-18. PTEN is a well-known tumor suppressor gene that has negative effects on cellular processes, initiating or sustaining malignant phenotypes, such as tumor growth, apoptosis and metastasis via inhibition of the PI3K/Akt pathway (Fang et al., 2007; Tian et al., 2010) . Many previous studies have shown the negative correlation between PTEN and tumor angiogenesis. For instance, PTEN reduces HIF-1a and VEGF expression levels, and inhibits tumor angiogenesis by the activation of PI3K/ Akt signaling in pancreatic cancer and hepatomacellular carcinoma Merritt et al., 2010) . Our data also demonstrated that PTEN was participating in the regulation of angiogenesis by Mel-18 via regulating both the Akt/MDM2 and Akt/FOXO3a pathways. Therefore, we suggest that PTEN might be a key downstream mediator of Mel-18 that contributes to the inhibition of tumor angiogenesis, and its tumor suppressive role might be effectively controlled by Mel-18. In our findings, downexpression of Mel-18 reduced the stability of the PTEN protein. Previous studies have shown the regulatory mechanism for PTEN stability. PTEN can be ubiquitinated and degradaded by several ubiquitin E3 ligases, such as NEDD4 and the X-linked inhibitor of apoptosis protein Wang et al., 2007; Van Themsche et al., 2009 ). Phosphorylation of PTEN by casein kinase 2 or GSK3b also controls PTEN stability by promoting ubiquitination (Torres and Pulido, 2001; Al-Khouri et al., 2005) . Unlike casein kinase 2 and GSK3b, ROCK1-mediated PTEN phosphorylation at S380 upregulates the stablilty of PTEN (Vemula et al., 2010) . Moreover, DJ-1, which forms an ubiquitin E3 ligase complex with Parkin and PINK1, negatively regulates PTEN proteins (Kim et al., 2005; Xiong et al., 2009) . When checked DJ-1 expression in our experimental system, it was not altered by Mel-18 (data not shown). Because we have shown that Mel-18 negatively regulates the RING1b E3 ubiqutin ligase activity (Qian et al., 2010) , we examined whether PTEN is a target of RING1b. However, the expression of PTEN was not changed by RING1b activity (data not shown). Furthermore, in our data, downexpression of Mel-18 enhanced PTEN protein in a proteasome dependent manner, but it did not affect the ubiquitination of PTEN (data not shown), indicating that Mel-18 might regulate PTEN expression through ubiquitin-independent proteasomal degradation. Taken together, we determined that Mel-18 might regulate PTEN expression through ubiquitinindependent proteasomal degradation. To clarify the exact mechanism of PTEN degradation by Mel-18, further study is needed.
The function of Mel-18 in human cancer has not been fully defined, but recent studies have demonstrated the association between decreased Mel-18 expression and poor prognosis in various cancers including breast, prostate and gastric cancers . Previously, we have also reported that Mel-18 expression is lower in human breast tumor tissues when compared with normal tissues (Lee et al., 2008) . It remains controversial whether Mel-18 has tumor suppressive function as an anti-angiogenic factor, because a recent study demonstrated that Mel-18 promotes tube formation in HUVEC (Jung et al., 2010) , and this is contrary to our results. However, in our present study, we showed not only the inhibition of in vitro tube formation by Mel-18 overexpression in HUVECs, but also enhanced expression of phospho-Akt, HIF-1a, and microvessel density by Mel-18 knockdown in the breast tumor xenograft model. Furthermore, our results demonstrated that decreased Mel-18 expression enhanced tumor volume in an in vivo model. These data could be strong evidence that Mel-18 has a tumor suppressive function in human breast cancer, as a potential negative regulator of tumor angiogenesis both in vitro and in vivo. In addition, our results support previous clinical results regarding the correlation between the low expression of Mel-18 and poor prognosis in human cancers. HIF-1a expression has been used as a prognosis predictor that is associated with poor prognosis in many cancers including breast, colorectal and pancreatic cancers (Hoffmann et al., 2008; Baba et al., 2010) . Therefore, our data emphasize the importance of Mel-18 as a novel negative regulator of HIF-1a and suggest Mel-18 as a potential biomarker for cancer diagnosis.
Collectively, our study demonstrates that Mel-18 regulated tumor angiogenesis by controlling HIF-1a expression and transcriptional activity via the activation of PTEN/PI3K/Akt signaling, suggesting that this novel role of Mel-18 could explain its tumor suppressive activity. It may also suggest that loss of Mel-18 could possibly be a poor prognostic marker in human cancers. 
Materials and methods
Cell culture and reagents MCF7, SK-BR-3 and ZR-75-1 breast cancer cells were cultured in DMEM without phenol red (Welgene, Daegu, Republic of Korea), containing 10% fetal bovine serum. 293T and 293gpg retrovirus packaging cell lines, and HUVECs were cultured as previously described (Kim et al., 2007) . To create the hypoxic condition, the cells were treated with 100 mM CoCl 2 (Sigma, St Louis, MO, USA) for 6 h. To inhibit the proteasomal degradation, the cells were treated with 40 mM MG132 (Calbiochem, San Diego, CA, USA) for 6 h. The PI3K inhibitor LY294002 was from Sigma.
Generation of lentiviral short hairpin RNA (shRNA) and/or retroviral construct, and virus infection The retroviruses were produced as previously described (Kim et al., 2007; Hoffmann et al., 2008) . pLB lentiviral vector and control shRNA plasmid were provided by Sang-Kyung Lee (Hanyang University, Seoul, Korea). To establish a lentiviral Mel-18 shRNA expression system, the sense and antisense oligonucleotides, including the Mel-18 short interfering RNA sequence (GGACATCGCCTACATCTACT) were annealed and inserted into the pLB vector. To make ZR-75-1 cells stably reconstituted with PTEN, we inserted PTEN complementary DNA into the lentivral pLVX vector (Clontech Lab Inc. CA, USA). 293T cells were transfected with the each lentiviral vector with packaging mix using Lipofectamine (Invitrogen, Carlsbad, CA, USA). After transfection for 48 h, the medium containing the viruses was harvested, filtered and transferred to target cells with 6 mg/ml polybrene (Sigma).
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Total RNA isolation and RT-PCR were performed as previously described (Kim et al., 2007) . The following specific Mel-18 primers were used: forward, 5 0 -GTACTTCATCG ACGCCACCACTA TC-3 0 ; reverse, 5 0 -CTCGTCCTCGTAC AGAACCTCCA-3 0 . Other primers were as described previously (Kim et al., 2007) .
Immunoblotting and Immunoprecipitation
Immunoblotting was performed as previously described (Hoffmann et al., 2008) . For immunoprecipitation, lysate was incubated with specific antibodies overnight at 4 1C. The precipitates were reacted with protein G-agarose for 3 h at 4 1C, washed with ice-cold PBS, and analyzed by the immunoblotting as described above. The following antibodies were used: antibodies against Akt, S473 phospho-Akt, phospho-MAPK, FOXO3a, phospho-FOXO3a from Cell Signaling Technology (Beverly, MA, USA); HIF-1a (H-206), VEGF (147), , and PTEN (A2B1) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); HIF-1a antibody from BD Biosciences (Palo Alto, CA, USA); total MAPK from Zymed Laboratories (South San Francisco, CA, USA); MECA-32 from BD Pharmigen (San Diego, CA, USA); b-actin from Sigma.
Chromatin immunoprecipitation (ChIP) assay and real-time PCR ChIP assays were performed following the manufacturer's instructions provided by a ChIP assay kit (Upstate Biotechnology, Lake Placid, NY, USA). For quantification of the ChIP analysis, we carried out real-time PCR as described by the manufacturers (Bio-Rad, El Cajon, California, USA) besides normal PCR analysis. For PCR and real-time PCR, the primer specific to VEGF-promoter (forward, 5 0 -GACGTT CCTTAGTGCTGGCGGGTAGGTTTGA-3 0 ; reverse, 5 0 -GGC ACCAAGTTTGTGGAGCTGAGAAC-3 0 ) was used.
Cell fractionation and Immunocytochemistry
Cell fractionation and immunocytochemistry were performed as previously described (Hoffmann et al., 2008) . Phycoerythrinconjugated anti-rabbit IgG (1:200) were used for FOXO3a staining in immunocytochemistry.
Luciferase reporter assay
The cells were seeded in a 12-well plate and transfected with a reporter construct, 100 ng HRE-Luc and VEGF-Luc, together with b-galactosidase expression vector (100 ng) using the FuGENE 6 reagent (Roche Diagnostics Corp., Indianapolis, IN, USA). To produce hypoxia conditions, the cells were cultured with 100 mM CoCl 2 for 6 h just before the harvest. After transfection for 48 h, a luciferase reporter assay was performed as has been previously described (Kim et al., 2007) .
Tube formation assay
To establish Mel-18 overexpressing HUVECs, retroviruses encoding Mel-18 cDNA were infected into HUVECs for 12 h, and the cells were placed in fresh medium and additionally cultured for 48 h, and were then seeded on a layer of Matrigel (BD Biosciences, San Jose, CA, USA) in a 96-well plate without or with the 100 mM CoCl 2 . The closed networks of vessel-like tubes were counted under an inverted light microscope. Incomplete networks were excluded.
Preparation of conditioned media and ELISA After incubation the control and Mel-18 knockdown MCF7 cells in normoxia and hypoxia condition with CoCl 2 treatment, the culture media were collected and concentrated by using amicon (Millipore, Billerica, MA, USA). The collected supernatants were used as conditioned media for HUVECs and subjected to in vitro tube formation assay as above. The amount of released VEGF was measured by ELISA according to the instructions of the manufacturer (R&D systems, Wiesbaden, Germany).
Xenograft evaluation
Five-week-old female NOD/SCID mice were purchased from the Korea Research Institute of Bioscience & Biotechnology (KRIBB, Daejeon, Korea). An estrogen pellet was implanted subcutaneously in the back of each mouse's neck. After one week, control or Mel-18-knocked-down MCF7 cell lines were resuspended in 100 ml of 1:1 matrigel mixed DMEM-10% FBS and directly injected into the fat pads of 7-week-old NOD/ SCID mice. Tumor measurement was done twice a week for 4 weeks using digital calipers, and tumor volume was calculated by the formula: 1/2 Â long diameter Â short diameter 2 .
Immunohistochemistry
Cells were inoculated into the mammary fat pads of NOD/ SCID mice. The tumor took 4-5 weeks to form and then the tumor was dissected. Left-side tumors were frozen at À70 1C and right-side tumors were fixed in 10% formalin and embedded in paraffin blocks. Frozen sections were cut and fixed in cold acetone for 10 min. Endogenous peroxidase activity in acetone-fixed tissue was inhibited by incubating slides for 5 min with 3% H 2 O 2 water. Sections were rinsed with PBS twice for 5 min and incubated in blocking solution (Immunotech, Marseille, France). Sections from formalinfixed tissues were mounted onto adhesive-coated slides and incubated at 55 1C for 30 min. Sections were deparaffinized, hydrated and soaked in 3% hydrogen peroxide solution to remove endogenous peroxidase activity. Sections were washed with PBS three times and incubated in 0.0 l M sodium citrate buffer (pH 6.0) for 10 min. After antigen retrieval, sections were washed in Tris buffer saline containing 0.05% Tween-20 and incubated in blocking buffer. Slides were incubated overnight at 4 1C with primary antibodies. Each primary antibody was detected by an UltraTek HRP kit (Immunotech).
